For the year ending 2025-12-31, MIRA had $3,513,990 increase in cash & cash equivalents over the period.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -10,442,485 |
| Stock-based compensation expense | 6,313,167 |
| Unrealized loss on short-term investments | -35,212 |
| Prepaid expenses | -26,583 |
| Trade accounts payable and accrued expenses | -594,146 |
| Net cash used in operating activities | -4,661,669 |
| Offering costs | 292,470 |
| Proceeds from related party | 572,865 |
| Proceeds from common stock option exercises | 888,282 |
| Proceeds from sale of common stock | 7,006,982 |
| Net cash provided by financing activities | 8,175,659 |
| Net increase (decrease) in cash | 3,513,990 |
| Cash, beginning of year | 2,832,931 |
| Cash, end of year | 6,346,921 |
MIRA PHARMACEUTICALS, INC. (MIRA)
MIRA PHARMACEUTICALS, INC. (MIRA)